Pink SheetThe Inflation Reduction Act (IRA)’s $2,000 Part D spending cap, which took effect on 1 January, is projected to help more than 11 million Medicare beneficiaries save $7bn on prescription drugs, accord
ScripPlanning for top-seller Jakafi’s (ruxolitinib) US patent expiration in 2028, Incyte reported positive top-line data from a pair of Phase III trials of selective JAK1 inhibitor povorcitinib in hidraden
ScripIonis licensed global rights to Phase II polycythemia vera (PV) candidate sapablursen to Ono Pharmaceutical on 11 March. The deal provides near-term and longer-term revenue for a drug candidate the an
ScripTakeda Pharmaceutical envisions a potentially significant market in polycythemia vera (PV) for rusfertide, which it is developing together with Protagonist Therapeutics, after reporting positive Phase